NextFlex podcast spotlights hybrid electronics for biotech including PDS Biotechnology; AVIXA InfoComm EDGE Dubai
- NextFlex explains design and scalable manufacturing that move prototypes into regulated production — vital for companies like PDS Biotechnology.
- Transition to regulated production is critical for PDS Biotechnology when integrating electronic monitoring, drug‑delivery interfaces, or diagnostics.
- Hybrid electronics help PDS Biotechnology integrate monitoring, drug‑delivery, and companion diagnostics with biologic therapies in medical settings.
Industry briefing: hybrid electronics meeting biotech needs
NextFlex launches podcast to explain hybrid electronics' path to market
NextFlex, the U.S. Hybrid Electronics Manufacturing Innovation Institute, is rolling out a new podcast series, Electronics at the Edge, to spotlight breakthroughs and commercial pathways in hybrid electronics. Episode one, "At the Edge of Innovation: What Are Hybrid Electronics?", features Executive Director Dr. Dan Gamota and frames hybrid electronics as reshaping the intersection of form, function and manufacturing. The series aims to make technical and programmatic lessons accessible while showing how collaboration accelerates commercialization across industry, government and academia.
The podcast foregrounds implications for the life sciences industry, where wearable sensors, point‑of‑care diagnostics and implantable devices increasingly rely on hybrid electronic assemblies. NextFlex hosts unpack how design choices and scalable manufacturing practices move prototypes into regulated production — a transition that companies such as PDS Biotechnology and other biotech firms find critical when integrating electronic monitoring, drug‑delivery interfaces or companion diagnostics with biologics. Guests and hosts discuss concrete examples of hybrid approaches applied to constrained form factors and harsh environments common in medical settings.
Later episodes map NextFlex’s consortium model and project‑call process, offering a playbook for multidisciplinary projects that bridge R&D and production. Episode two previews an overview of NextFlex’s commercial services with Dr. Scott Miller, and episode three examines how project calls drive results with Dr. Nick Morris. The series stresses measurable pathways from concept to market through networks, standards and manufacturing services, aiming to reduce technical risk and shorten timelines for commercialization of bioelectronic solutions relevant to biotech developers.
AVIXA stages experiential InfoComm EDGE in Dubai
AVIXA announces InfoComm EDGE, a two‑day experiential pro AV event at Dubai’s Festival Arena on Oct. 27–28, 2026, designed to let senior buyers see and experience integrated technology through live activations rather than traditional booths. The event targets stakeholders across government, enterprise, education and entertainment and invites integrators and manufacturers to submit designs and sponsorships.
Organisers say the format focuses on narrative‑led journeys and standards‑aligned showcases to help decision‑makers visualise complex solutions and reduce deployment risk. The Festival Arena offers more than 7,200 square metres of indoor and outdoor space and aims to pair local design and deployment communities with global buyers.
Related Cashu News

CRISPR Therapeutics AG Achieves Financial Progress Amid Advancements in Gene-Editing Portfolio
CRISPR Therapeutics AG (Ticker: UNDEFINED) showcases a pivotal moment in its financial journey with the release of its results for the first quarter of 2026. Highlighting a revenue of $1.46 million, t…

MetaVia to Present Innovative Cardiometabolic Research at 2026 ADA Scientific Sessions
MetaVia is set to showcase its innovative research in cardiometabolic diseases at the upcoming American Diabetes Association (ADA) Scientific Sessions in 2026, following the acceptance of three late-b…

Ionis Pharmaceuticals Advances TRYNGOLZA for Hypertriglyceridemia and Diranersen for Alzheimer's Disease
Ionis Pharmaceuticals has made headlines in the biotechnology sector with the promising potential of its drug TRYNGOLZA, which is designed to treat severe hypertriglyceridemia. During a recent healthc…

ImmunityBio Partners with BCG Laboratory to Enhance Bladder Cancer Treatment Supply and Options
ImmunityBio has secured a critical partnership with Japan's BCG Laboratory to enhance the supply of Bacillus Calmette-Guérin (BCG) in the United States, addressing an urgent need in the treatment of b…